Veille Pharma
Follow
19.1K views | +5 today
Veille Pharma
Responsable des études chez VIGIEPHARMA. Mes posts n'engagent que moi. http://www.vigiepharma.fr/
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

New Data on Odanacatib, Merck’s Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research - Yahoo! Finance

New Data on Odanacatib, Merck’s Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The American Society for Bone and Mineral Research - Yahoo! Finance | Veille Pharma | Scoop.it

SAN DIEGO--(BUSINESS WIRE)-- New clinical and pre-clinical data on Merck’s odanacatib, an investigational cathepsin K (cat-K) inhibitor for the treatment of osteoporosis in post-menopausal women, were presented at the 33rd Annual Meeting of The American Society for Bone and Mineral Research (ASBMR) in San Diego. The data were presented in an oral presentation and five posters.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Amgen's Prolia wins new uses, performs in study

It's a good news-good news day for Amgen ($AMGN). The company's new bone drug is gathering indications--and potential sales--like a snowball rolling downhill. Under the name Prolia, the drug won FDA approval for bone loss in breast cancer patients using aromatase inhibitors. And it got the FDA nod for prostate cancer patients undergoing androgen-deprivation therapy.

more...
No comment yet.